10x Genomics (TXG) Change in Accured Expenses (2018 - 2026)

10x Genomics (TXG) has 9 years of Change in Accured Expenses data on file, last reported at -$613000.0 in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses changed N/A year-over-year to -$613000.0; the trailing twelve-month figure through Mar 2026 stood at -$5.8 million (down 135.31% YoY), and the FY2025 full-year result was -$5.2 million, down 241.02% from the prior year.
• Change in Accured Expenses grew to -$613000.0 in Q1 2026, from -$7.4 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $19.1 million in Q4 2023 to a low of -$13.3 million in Q1 2022.
• A 5-year average of $1.7 million and a median of $2.2 million in 2023 frame the typical range for Change in Accured Expenses.
• Across the five-year window, Change in Accured Expenses surged 651.57% in 2022 and slumped 7772.05% in 2024, its largest moves.
• Tracing TXG's Change in Accured Expenses over 5 years: stood at $4.3 million in 2022, then jumped by 347.7% to $19.1 million in 2023, then sank by 80.53% to $3.7 million in 2024, then slumped by 299.44% to -$7.4 million in 2025, then soared by 91.76% to -$613000.0 in 2026.
• Business Quant data shows TXG's Change in Accured Expenses at -$613000.0 in Q1 2026, -$7.4 million in Q4 2025, and $5.2 million in Q3 2025.